$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy

2024-06-13

2026-06

2027-01

20

Study Overview

Promitil Treatment of Patients With Solid Tumors Associated With Deleterious Mutations Who Have Progressed After Therapy

This multicenter Phase 2a study was designed to evaluate the safety, tolerability, and efficacy of Promitil in patients with recurrent ovarian cancer and inoperable, locally advanced or metastatic pancreatic cancer, which bears deleterious germline or somatic mutations in BRCA1, BRCA2, or HRD (homologous recombination deficiency) -related genes. Based on reported preclinical and clinical efficacy of Mitomycin C in BRCA-mutated tumors, and together with the demonstrated improved safety profile of Promitil in humans, it is expected that this liposomal formulation will have a favorable therapeutic index and significant clinical antitumor activity in patients with tumors bearing BRCA 1/2 and/or PALB2 mutations.

The study will include a Screening, Treatment Phase and Long-Term Follow-up (LTFU) Phase. Upon signing the informed consent form, all subjects will undergo screening procedures to assess eligibility within 21 days prior to receiving study drug. Eligible subjects will be intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Promitil until disease progression, death, unacceptable toxicity or withdrawal of consent. During the 6-month Treatment Phase, safety assessments will be conducted at each study visit (Days 1, 2, 4,8 and 14 of Cycle 1, Day 1 of Cycle 2 and Cycles 4 and beyond and Days 1, 2 4,and 8 of Cycle 3). Safety will be assessed by measurement of weight, physical examinations, vital signs, ECG recordings, blood chemistry, hematologic and urinalysis parameters, and review of Adverse and Serious Adverse events (SAEs) and concomitant medications. Response will be assessed by CT/MRI/PET-CT scans and biomarker levels, with imaging conducted every 12 weeks (every 3 treatment cycles).For patients who stopped receiving Promitil for any reason other than disease progression, response will continue to be assessed every 12 weeks, until disease progression, death or withdrawal of consent, but no later than 1 year from first dose of Promitil. Once study treatment ends, all subjects will be followed up long-term, with survival status assessed every 3 months for up to 1 year or until death, the earlier of the two.

  • Cancer of Ovary
  • Pancreatic Ductal Adenocarcinoma
  • DRUG: Promitil
  • PROM-2301

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2024-06-17  

N/A  

2025-05-06  

2024-06-24  

N/A  

2025-05-07  

2024-06-27  

N/A  

2025-05  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Pancreatic cancer

Eligible subjects with pancreatic cancer will be intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Each cycle may be extended for up to 3 additional weeks (i.e., up to a total of 7 weeks from previous Da

DRUG: Promitil

  • The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Pr
EXPERIMENTAL: Ovarian cancer

Eligible subjects with ovarian cancer will be intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Each cycle may be extended for up to 3 additional weeks (i.e., up to a total of 7 weeks from previous Day 1

DRUG: Promitil

  • The 10 patients recruited in each of the cohorts will receive intravenously (IV) administered 2.0 mg/kg Promitil on Day 1 of each 28-day cycle, for up to 6 cycles. Subjects who complete the 6-cycle Treatment Phase have the option to continue to receive Pr
Primary Outcome MeasuresMeasure DescriptionTime Frame
Progression-free survival (PFS) rate at Month 6defined as the proportion of patients who are alive and without radiological or clinical progression, based on RECIST 1.124 weeks
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Incidence, severity, and duration of treatment-emergent adverse events (TEAEs)TEAEs assessed by NCI Common Toxicity Criteria Adverse Events (CTCAE v5.0).30 weeks
Objective response rate (ORR):ORR: proportion of patients with partial or complete response (PR or CR, respectively), based on RECIST 1.1 criteria24 weeks
Duration of response (DOR)DOR: defined as the time from first evidence of confirmed objective response to the first occurrence of disease progression or death from any cause24 weeks
Disease control rate (DCR)DCR :defined as proportion of subjects alive and free of disease progression with either complete response (CR), partial response (PR) or stable disease (SD)24 weeks
Overall survival (OS):OS: time from first dose of Promitil to date of death from any cause52 weeks
To assess the changes in tumor biomarker levels following treatment with PromitilChanges from baseline in CA19-9, CA125, CA15.3 and/or CEA blood levels24 weeks

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. 18 years of age or older on day of consent 2. Patient with either one of the following histologically or cytologically confirmed, deemed incurable malignancies:
    1. Recurrent ovarian cancer 2. Inoperable, locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) 3. Patient with PDAC measurable by RECIST 1.1. Previously irradiated lesions may be considered measurable if there has been demonstrated progression in these lesions. Ovarian cancer patients can have either measurable or non-measurable lesions (i.e., ovarian cancer patients with mostly ascites or pleural effusion are eligible) 4. Tumor with a known pathogenic or likely pathogenic germline or somatic mutation in BRCA1, BRCA2 or HRD-related genes as determined by a Clinical Laboratory Improvement Amendments (CLIA)-certified or equivalently accredited laboratory. Note: Patients with positive HRD score can be eligible regardless of any evidence for germline or somatic mutations 5. Patient received at least 1 line of chemotherapy for advanced pancreatic adenocarcinoma or ovarian cancer. Prior neoadjuvant and adjuvant chemotherapy are allowed, and platinum re-challenge is allowed for ovarian cancer patients for whom it is felt to be in their best interests, as determined by the Investigator. Prior PARP inhibitor, hormonal, biological, or immunological therapy are allowed. Palliative radiation therapy is allowed, provided it was/will be completed ≥2 weeks prior starting trial therapy 6. Capable of providing written informed consent, which includes compliance with the requirements and restrictions listed in the consent form 7. ECOG performance status of 0 or 1 8. Adequate organ function as defined by:
    1. Absolute neutrophil count (ANC) ≥ 1500/µL 2. Platelet count ≥ 100,000/µL 3. Hemoglobin ≥ 9.5 g/dL 4. Hematocrit ≥30% 5. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) 6. AST and ALT ≤ 3 x ULN OR ≤ 5 x ULN in the presence of liver metastases 7. Albumin ≥ 3g/dL 8. INR<1.5 unless on anticoagulants 9. Creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 45 mL/minute (as calculated by the Cockcroft-Gault formula) 10. Estimated life expectancy of at least 3 months 11. Patients (men and women) of reproductive potential willing and able to use an acceptable method of birth control as approved by the PI 12. With the exception of alopecia and neuropathy, resolution of all acute toxic effects of any prior chemotherapy, surgery or radiotherapy to NCI CTCAE (Version 5.0) Grade ≤ 1 or to the baseline laboratory values as defined in Inclusion Criteria Number 8 and 9.
    Exclusion Criteria:
    1. Uncontrolled intercurrent illness including, but not limited to, severe or ongoing active infection, symptomatic congestive heart failure, unstable angina pectoris, serious cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements 2. Any other severe concurrent disease which, in the judgment of the investigator, would make the subject unsuited for treatment 3. History of chronic active hepatitis, including carriage of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless patient is adequately treated and shown to be serum virus-free 4. Evidence of active bleeding 5. Untreated brain metastases Note: Patients with brain metastases treated by surgery or radiation who are stable and symptom-free (≤ 4 mg dexamethasone/day) are eligible to participate in the study 6. Patient is pregnant or lactating 7. Prior intravenous treatment with MMC, either alone or in combination 8. Other anti-cancer treatment within 2 weeks before start of study drug 9. Other myelosuppressive treatment within 4 weeks before start of study drug 10. Treatment with other investigational drugs within 5 drug half-lives of day 1 of study drug 11. Patients with uncontrolled ascites that had more than one palliative abdominal tap up to 30 days prior to Screening

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Ora Rosengarten, MD, Shaare Zedek

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    • Gabizon A, Shmeeda H, Tahover E, Kornev G, Patil Y, Amitay Y, Ohana P, Sapir E, Zalipsky S. Development of Promitil(R), a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside. Adv Drug Deliv Rev. 2020;154-155:13-26. doi: 10.1016/j.addr.2020.07.027. Epub 2020 Aug 7.
    • Gabizon AA, Tahover E, Golan T, Geva R, Perets R, Amitay Y, Shmeeda H, Ohana P. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients. Invest New Drugs. 2020 Oct;38(5):1411-1420. doi: 10.1007/s10637-020-00897-3. Epub 2020 Jan 18.
    Treat yourself

    Let Us Take Care Of You

    BOOK AN APPOINTMENT ⟶
    footer logo

    About

    Events

    Fundraising

    Contact Us

    Facebook-f Instagram

    NPCF was founded on May 29, 2009 and is a 501(c)(3) organization. All donations are tax deductible.

    The information and services provided by the National Pancreatic Cancer Foundation are for informational purposes only. The information and services are not intended to be substitutes for professional medical advice, diagnosis or treatment. The National Pancreatic Cancer Foundation does not recommend nor endorse any specific physicians, products or treatments even though they may be mentioned on this site.

    Copyright © 2025 – National Pancreatic Cancer Foundation | All Rights Reserved

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate